CN111171060A - Pyridine-containing boron dipyrrole and quaternary ammonium salt photosensitizer thereof, and preparation method and application thereof - Google Patents
Pyridine-containing boron dipyrrole and quaternary ammonium salt photosensitizer thereof, and preparation method and application thereof Download PDFInfo
- Publication number
- CN111171060A CN111171060A CN201811238213.2A CN201811238213A CN111171060A CN 111171060 A CN111171060 A CN 111171060A CN 201811238213 A CN201811238213 A CN 201811238213A CN 111171060 A CN111171060 A CN 111171060A
- Authority
- CN
- China
- Prior art keywords
- compound
- pyridine
- quaternary ammonium
- ammonium salt
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title claims abstract description 56
- 239000003504 photosensitizing agent Substances 0.000 title claims abstract description 29
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 150000003242 quaternary ammonium salts Chemical class 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- BVDLHLPSFYRKIC-UHFFFAOYSA-N N1C=CC=C1.N1C=CC=C1.[B] Chemical compound N1C=CC=C1.N1C=CC=C1.[B] BVDLHLPSFYRKIC-UHFFFAOYSA-N 0.000 title description 3
- 150000001875 compounds Chemical class 0.000 claims abstract description 50
- -1 pyridine quaternary ammonium salt Chemical class 0.000 claims abstract description 13
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 12
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 8
- 206010008342 Cervix carcinoma Diseases 0.000 claims abstract description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims abstract description 3
- 201000010881 cervical cancer Diseases 0.000 claims abstract description 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical group C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims description 7
- 201000011510 cancer Diseases 0.000 claims description 6
- 229940125782 compound 2 Drugs 0.000 claims description 4
- 229940125904 compound 1 Drugs 0.000 claims description 3
- 239000002202 Polyethylene glycol Chemical group 0.000 claims description 2
- 125000003827 glycol group Chemical group 0.000 claims description 2
- 229920001223 polyethylene glycol Chemical group 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 229940126214 compound 3 Drugs 0.000 claims 1
- 229940125898 compound 5 Drugs 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002611 ovarian Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 abstract description 14
- 238000003786 synthesis reaction Methods 0.000 abstract description 14
- 210000004881 tumor cell Anatomy 0.000 abstract description 14
- 230000000694 effects Effects 0.000 abstract description 6
- 238000012360 testing method Methods 0.000 abstract description 5
- 238000000338 in vitro Methods 0.000 abstract description 4
- 206010009944 Colon cancer Diseases 0.000 abstract description 3
- 208000029742 colonic neoplasm Diseases 0.000 abstract description 3
- 229940079593 drug Drugs 0.000 abstract description 3
- 208000017983 photosensitivity disease Diseases 0.000 abstract description 3
- 231100000434 photosensitization Toxicity 0.000 abstract description 3
- 206010005003 Bladder cancer Diseases 0.000 abstract description 2
- 206010006187 Breast cancer Diseases 0.000 abstract description 2
- 208000026310 Breast neoplasm Diseases 0.000 abstract description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 abstract description 2
- 206010033128 Ovarian cancer Diseases 0.000 abstract description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract description 2
- 206010060862 Prostate cancer Diseases 0.000 abstract description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract description 2
- 208000000453 Skin Neoplasms Diseases 0.000 abstract description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract description 2
- 206010017758 gastric cancer Diseases 0.000 abstract description 2
- 230000005764 inhibitory process Effects 0.000 abstract description 2
- 201000005202 lung cancer Diseases 0.000 abstract description 2
- 208000020816 lung neoplasm Diseases 0.000 abstract description 2
- 201000000849 skin cancer Diseases 0.000 abstract description 2
- 201000011549 stomach cancer Diseases 0.000 abstract description 2
- 201000005112 urinary bladder cancer Diseases 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 54
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 22
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 21
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- 239000007787 solid Substances 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 238000004440 column chromatography Methods 0.000 description 12
- 229910052786 argon Inorganic materials 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 238000001035 drying Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 238000005160 1H NMR spectroscopy Methods 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 9
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 8
- 239000004698 Polyethylene Substances 0.000 description 8
- 210000003470 mitochondria Anatomy 0.000 description 7
- 238000003756 stirring Methods 0.000 description 7
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000005406 washing Methods 0.000 description 6
- 238000002428 photodynamic therapy Methods 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 description 4
- NUJPCHHXTCYXTQ-UHFFFAOYSA-N 9-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]carbazole-3-carbaldehyde Chemical compound O=CC1=CC=C2N(CCOCCOCCOC)C3=CC=CC=C3C2=C1 NUJPCHHXTCYXTQ-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 3
- MFFMQGGZCLEMCI-UHFFFAOYSA-N 2,4-dimethyl-1h-pyrrole Chemical compound CC1=CNC(C)=C1 MFFMQGGZCLEMCI-UHFFFAOYSA-N 0.000 description 3
- ULUNQYODBKLBOE-UHFFFAOYSA-N 2-(1h-pyrrol-2-yl)-1h-pyrrole Chemical compound C1=CNC(C=2NC=CC=2)=C1 ULUNQYODBKLBOE-UHFFFAOYSA-N 0.000 description 3
- PAPNRQCYSFBWDI-UHFFFAOYSA-N DMP Natural products CC1=CC=C(C)N1 PAPNRQCYSFBWDI-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M sodium bicarbonate Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- ZKSVYBRJSMBDMV-UHFFFAOYSA-N 1,3-diphenyl-2-benzofuran Chemical compound C1=CC=CC=C1C1=C2C=CC=CC2=C(C=2C=CC=CC=2)O1 ZKSVYBRJSMBDMV-UHFFFAOYSA-N 0.000 description 2
- IUDNRKGPFWUYIC-UHFFFAOYSA-N 2-[2-(2-methoxyethoxy)ethoxy]ethyl 4-methylbenzenesulfonate Chemical compound COCCOCCOCCOS(=O)(=O)C1=CC=C(C)C=C1 IUDNRKGPFWUYIC-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- TZKVZEPOBZYEDG-UHFFFAOYSA-N 9-[2-[2-(2-methoxyethoxy)ethoxy]ethyl]carbazole Chemical compound C1=CC=C2N(CCOCCOCCOC)C3=CC=CC=C3C2=C1 TZKVZEPOBZYEDG-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- QQVDYSUDFZZPSU-UHFFFAOYSA-M chloromethylidene(dimethyl)azanium;chloride Chemical compound [Cl-].C[N+](C)=CCl QQVDYSUDFZZPSU-UHFFFAOYSA-M 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical group 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 description 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010048723 Multiple-drug resistance Diseases 0.000 description 1
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 150000001638 boron Chemical class 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004098 cellular respiration Effects 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 231100000517 death Toxicity 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- OVTCUIZCVUGJHS-UHFFFAOYSA-N dipyrrin Chemical compound C=1C=CNC=1C=C1C=CC=N1 OVTCUIZCVUGJHS-UHFFFAOYSA-N 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 239000012038 nucleophile Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000001007 phthalocyanine dye Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- QJZUKDFHGGYHMC-UHFFFAOYSA-N pyridine-3-carbaldehyde Chemical compound O=CC1=CC=CN=C1 QJZUKDFHGGYHMC-UHFFFAOYSA-N 0.000 description 1
- BGUWFUQJCDRPTL-UHFFFAOYSA-N pyridine-4-carbaldehyde Chemical compound O=CC1=CC=NC=C1 BGUWFUQJCDRPTL-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000004102 tricarboxylic acid cycle Effects 0.000 description 1
- JLGLQAWTXXGVEM-UHFFFAOYSA-N triethylene glycol monomethyl ether Chemical compound COCCOCCOCCO JLGLQAWTXXGVEM-UHFFFAOYSA-N 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/022—Boron compounds without C-boron linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the field of drug synthesis, relates to a pyridine-containing BODIPY compound with a general formula (I) and a quaternary ammonium salt thereof, and particularly relates to a pyridine quaternary ammonium salt photosensitizer, a preparation method thereof and medical application thereof. The compound has good anti-tumor activity through in vitro photosensitization efficiency and tumor cell inhibition activity tests, and the result shows that the compound has good anti-tumor activity, can be further used for preparing a new anti-tumor medicament and is used for treating wide tumors without specificity, such as gastric cancer, breast cancer, prostatic cancer, lung cancer, colon cancer, bladder cancer, ovarian cancer, skin cancer and cervical cancer.
Description
Technical Field
The invention belongs to the field of drug synthesis, and relates to a novel pyridine-containing BODIPY and quaternary ammonium salt photosensitizer thereof, and a preparation method and application thereof. In particular to a pyridine-containing boron dipyrrole and quaternary ammonium salt photosensitizer thereof, a preparation method and application thereof in pharmacy.
Background
Malignant tumors have been reported to be common diseases seriously harming the life health of people. According to incomplete statistics, there are about 2000 million new cases worldwide each year; the number of new cases is 160-200 ten thousand per year and 130 ten thousand deaths in China. The existing methods commonly used for treating malignant tumors comprise radiotherapy, chemotherapy, surgical operation treatment and the like, and research shows that about 50% of patients in clinical diagnosis of primary tumors have distant metastasis due to the early metastatic capacity of tumor cells, and the tumor cells are rapidly increased and easily mutated, so that multiple drug resistance is frequently generated in chemotherapy, and chemotherapy failure is caused; according to relevant statistics, more than 90% of the total tumor cell markers are related to multidrug resistance of tumor cells, and the antitumor drugs applied in current clinical practice far from meeting the treatment requirements.
The literature describes Photodynamic therapy (PDT) as a new technique for diagnosing and treating tumors and other pathological target tissues using Photodynamic effects; photosensitizers targeted to tumor sites and oxygen molecules in tissues under irradiation with light of a specific wavelength: (3O2) to generate Reactive Oxygen Species (ROS) to further oxidize tumor cells and realize the effect of killing the tumor cells. It is considered that photodynamic therapy is a potential tumor therapy technology, and the systemic toxicity of the whole body is greatly reduced by tumor targeting positioning of the photosensitizer and selective irradiation of tumor sites.
BODIPY photosensitizer has become a research hotspot in the field of light treatment in recent years due to the advantages of high molar extinction coefficient, high singlet oxygen yield, photobleaching resistance, high light-dark toxicity ratio and the like. Researches show that the maximum absorption peak of the BODIPY photosensitizer can be adjusted to a near infrared region through proper modification, so that the tissue penetrability in PDT is effectively increased; heavy atoms can enhance spin-orbit coupling, thereby facilitating inter-hopping and increasing the yield of singlet oxygen, which is called as "heavy atom effect"; however, it has been shown that too many halogen atom-substituted boron dipyrromethene BODIPY photosensitizers are not conducive to increasing their singlet oxygen yield, and that increasing halogen atoms increases the depth of penetration of the photosensitizer into dark toxic tissue is a major challenge for practical photodynamic therapy; biocompatible and highly efficient Near Infrared (NIR) -absorbing carbazole substituted BODIPY (Car-BDP) molecules are reported as a class of imageable deep tissue active PDT photosensitizers; Car-BDP has a strong, broad absorption band in the near infrared spectrum (600-800nm) and a very high singlet oxygen yield.
Based on the industry consensus: the photosensitizer should have good water solubility and lipid solubility, especially amphiphilicity; on one hand, the water-soluble liposome has water solubility and is convenient to administer, and on the other hand, the liposome has certain lipid solubility and is beneficial to the permeation of the drug through cell membranes. Mitochondria are the main site of cellular respiration, and both tricarboxylic acid cycle and oxidative phosphorylation are carried out in mitochondria, which when dysfunctional will lead to a range of diseases such as sepsis, ischemia-reperfusion injury, diabetes, and the like. The difference of the structure and the function of the tumor cell mitochondria and the normal cell mitochondria, the transmembrane potential of the tumor cell mitochondria is obviously higher than that of the normal cell, and the medicament is selectively accumulated in the tumor cell mitochondria on the basis of the difference, thereby inhibiting the growth of the tumor cell and triggering the apoptosis.
Based on the current state and foundation of the prior art, based on research on fluorescent probes, quaternary pyridinium salt can improve water solubility, impart mitochondrial targeting ability, and have lower toxicity (chem.Commun.,2013,49, 10620-10622; org.biomol.chem.,2013,11, 555-558); the inventor intends to provide a pyridine-containing BODIPY and its quaternary ammonium salt photosensitizer, and its preparation method and pharmaceutical use; the BODIPY structure containing pyridine and pyridine quaternary ammonium salt can meet the structural requirement of photosensitizer preparation, possibly improve the water solubility of the photosensitizer, and can target mitochondria to have better anti-tumor effect.
Disclosure of Invention
The invention aims to provide novel pyridine-containing BODIPY and quaternary ammonium salt compounds thereof with good anti-tumor activity based on the current situation and the foundation of the prior art, and the main advantages of the novel pyridine-containing BODIPY and the quaternary ammonium salt compounds thereof are long-wavelength absorption, good water solubility, mitochondrial targeting and the like.
The pyridine-containing BODIPY and quaternary ammonium salt photosensitizer compound thereof are BODIPY framework compounds containing pyridine, carbazole and polyethylene glycol chains, have a structure shown in a general formula (I),
more specifically, the pyridine-containing BODIPY and quaternary ammonium salt compound thereof of the present invention have the following structures:
the invention also aims to provide a preparation method of the novel pyridine-containing BODIPY and quaternary ammonium salt compounds thereof.
Taking compound 4 as an example, the preparation process of the compound of the present invention is as follows:
the compound disclosed by the invention is tested by in vitro photosensitization efficiency and cell level, and the result shows that the compound has good tumor inhibition activity, is obviously improved compared with a Car-BDP compound, and can be further developed into a novel pyridine-containing BODIPY and pyridine quaternary ammonium salt photosensitizer thereof and an antitumor drug.
The invention carries out in vitro tests, carries out anti-tumor activity tests on Hela cervical carcinoma cells, SW480 colon cancer cells and A549 non-small cell lung cancer cells respectively, and the results show that the compound of the invention shows better active oxygen yield and anti-tumor activity, wherein the compounds 1,3, 4 and 5 have D activityThe MF photosensitization efficiency value versus the zinc phthalocyanine dye (0.56) singlet oxygen yield value was 0.45, 0.44, 0.42 and 0.30, respectively; and IC of Compounds 2,4,6 on three tumor cells under the conditions tested50Less than 2. mu.M.
The compound of the invention can further prepare a novel pyridine-containing BODIPY photosensitizer.
Furthermore, the pyridine-containing BODIPY compound can be used for preparing a medicine for treating malignant tumors; the malignant tumor is wide nonspecific tumor, and is selected from gastric cancer, breast cancer, prostatic cancer, lung cancer, colon cancer, bladder cancer, ovarian cancer, skin cancer, and cervical cancer.
Detailed Description
EXAMPLE 1 Synthesis of Compound 1
1) Synthesis of 2- (2- (2-methoxyethoxy) ethoxy) ethyl 4-methylbenzenesulfonate
Dissolving 2g of 2- (2- (2-methoxyethoxy) ethoxy) ethanol and 2.2g of p-toluenesulfonic acid in a mixed solution of 80mL of dichloromethane and 80mL of tetrahydrofuran, adding 1.4mL of triethylamine dropwise, stirring at room temperature for 24H, monitoring the reaction by TLC, distilling off THF and DCM under reduced pressure, adding ethyl acetate and water each 150mL of which, shaking and separating, extracting an aqueous layer with ethyl acetate, combining organic layers, washing with saturated sodium chloride, drying with anhydrous sodium sulfate, distilling off the solvent under reduced pressure, and purifying by column chromatography, wherein EA is 1:4 to obtain a purified product 3.16g, the yield is 81.6%, and the content of MS (ESI) M/z ([ M + H ] M/z ([ M + ESI) M/z]+):319.1;
2) Synthesis of 9- (2- (2- (2-methoxyethoxy) ethoxy) ethyl) -9H-carbazole
2.4g of carbazole is dissolved in dry 15ml DMF, 577mg of 60% NaH (diethyl ether) is added, stirring is carried out for 30 minutes in ice bath under the protection of argon, and then stirring is carried out for 50 minutes at room temperature, thus obtaining the nitrogen anion nucleophile. The mixed solution was slowly dropped into a dry DMF solution of 5.4g of 2- (2- (2-methoxyethoxy) ethoxy) ethyl 4-methylbenzenesulfonate, stirred for 10 minutes in an ice bath under argon protection, and stirred for 30 minutes at room temperature. TLC monitored the reaction was complete and the reaction was quenched by addition of ice water. The aqueous layer was extracted with ethyl acetate (150 ml. times.3), the organic layers were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, and the solvent was distilled off under reduced pressureAnd purifying by column chromatography to obtain 3.2g of a product, wherein the yield is as follows: 75%, MS (ESI) M/z ([ M + H)]+):314.3;
3) Synthesis of 9- (2- (2- (2-methoxyethoxy) ethoxy) ethyl) -9H-carbazole-3-carbaldehyde
In a 25mL two-necked flask, 10mL dry DMF was added, ice-cooled, and protected with argon. Slowly dropwise adding 2.4ml of OCOCl3Stirring for 30 minutes under the ice bath condition to prepare a Vilsmeier reagent;
1.2g of 9- (2- (2- (2-methoxyethoxy) ethoxy) ethyl) -9H-carbazole are dissolved in 12mL of dry DMF solution. The prepared Vilsmeier reagent is added under ice bath condition, and stirred for 20 minutes under argon protection. After the temperature is returned to the room temperature, the temperature is raised to 80 ℃ and the mixture is stirred for 7 hours; the reaction was poured into ice water and saturated NaHCO was used3The Ph of the solution was adjusted to neutral, stirring was carried out for hours, the aqueous layer was extracted with ethyl acetate (150ml × 3), the organic layers were combined, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure, and column chromatography PE: EA ═ 1:4 was carried out to obtain 800mg of the product, yield: 62%, MS (ESI) M/z ([ M + H)]+):342.3;
4) Synthesis of 1,3,5, 7-tetramethyl-8- (2-pyridinyl) -4,4' -difluoroboradipyrrole
470mg of 2-pyridinecarboxaldehyde and 920mg of 2, 4-dimethylpyrrole are dissolved in 250mL of dry DCM, a catalytic amount of TFA is added, argon is used for protection, the mixture is stirred at room temperature for 24 hours, a part of DCM is evaporated under reduced pressure until the volume of the solution is 70mL, 1.5g of 2, 3-dichloro-5, 6-dicyan-p-benzoquinone is added, argon is used for protection, and the mixture is stirred at room temperature for 2 hours. Adding 7mL of triethylamine and 7mL of boron trifluoride diethyl etherate, stirring at room temperature overnight, removing the solvent under reduced pressure, dissolving the residual solid in 150mL of DCM, washing with water for three times, drying with anhydrous sodium sulfate, evaporating the solvent under reduced pressure, and purifying DCM/PE by column chromatography to obtain 390mg of an orange solid. Yield: 27%, MS (ESI) M/z ([ M + H)]+):326.2;
5) Synthesis of 2, 6-diiodo-1, 3,5, 7-tetramethyl-8- (2-pyridyl) -4,4' -difluoroboron dipyrrole
Compound 1,3,5, 7-tetramethyl-8- (2-pyridyl) -4,4' -difluoroboradipyrrole (100mg) was placed in a 25mL eggplant-shaped bottle, and HOAc/DCM ═ 1/3(6mL) was added thereto and dissolved. 340mg of N-iodosuccinimide was added, stirred at room temperature for 1 hour, and the reaction was monitored by TLC for completion20mL of saturated sodium thiosulfate solution, 20mL of water, 20mL of saturated NaHCO3Washing with an aqueous solution, drying over anhydrous sodium sulfate, evaporating the solvent under reduced pressure, and performing column chromatography on the solvent PE: EA ═ 1:1 to obtain 142mg of a brown solid, yield: 80%, MS (ESI) M/z ([ M + H)]+):578.0,1H NMR(400MHz,CDCl3)δ8.80(d,J=4.1Hz,1H),7.87(t,J=7.8Hz,1H),7.53–7.44(m,1H),7.40(d,J=7.8Hz,1H),2.64(s,6H),1.30(s,6H);
6) Synthesis of Compound 1
Dissolving the compound 2, 6-diiodo-1, 3,5, 7-tetramethyl-8- (2-pyridyl) -4,4 '-difluoroboron dipyrrole (100mg) and 9- (2- (2- (2-methoxyethoxy) ethoxy) ethyl) -9H-carbazole-3-formaldehyde (300mg) in toluene (10mL), adding glacial acetic acid (0.1mL) and piperidine (0.1mL), refluxing in a two-necked flask for 10H, removing the oil bath after the reaction is finished, extracting dichloromethane and water (25 mL. times.3), drying with anhydrous sodium sulfate, filtering, and evaporating the solvent to obtain the product CH-I-1, 3,5, 7-tetramethyl-8- (2-pyridyl) -4,4' -difluoroboron dipyrrole2Cl2Purification by column chromatography with MeOH (30:1, v/v, triethylamine 1%) afforded BODIPY 942 mg as a green solid. Yield: 19.8 percent of the total weight of the steel,1H NMR(400MHz,CDCl3)δ8.84(d,J=3.6Hz,1H),8.45(d,J=16.6Hz,2H),8.34-8.33(m,2H),8.15(d,J=7.7Hz,2H),7.90-7.83(m,4H),7.79-7.78(m,1H),7.51-7.48(m,8H),7.25-7.22(m,2H),4.51(t,J=5.5Hz,4H),3.89(t,J=5.4Hz,4H),3.52-3.51(m,4H),3.50-3.49(m,4H),3.45-3.44(m,4H),3.41-3.40(m,4H),3.32(s,6H),1.40(s,6H)。
example 2 Synthesis of Compound 2
Putting 140 mg of the compound in a sealed tube, adding 0.5mL of methyl iodide, reacting for 12 hours at 60 ℃, adding a small amount of DCM to dissolve the methyl iodide completely after the methyl iodide is volatilized completely, adding methyl tert-butyl ether to separate out a purple black solid, filtering, drying to obtain 29mg of a product with the yield of 65 percent,1H NMR(400MHz,CDCl3)δ8.68(s,1H),8.59(d,J=16.1Hz,2H),8.42(s,1H),8.35-8.34(m,2H),8.16-8.14(m,2H),8.05(s,1H),7.89-7.87(m,2H),7.80-7.75(m,2H),7.58-7.56(m,2H),7.50-7.49(m,5H),7.26-7.25(m,2H),4.54(s,7H),3.92-3.91(m,4H),3.54-3.53(m,4H),3.51-3.50(m,4H),3.46-3.65(m,4H),3.42-3.40(m,4H),3.32(s,6H),1.36(s,6H)。
example 3: synthesis of Compound 3
1) Synthesis of 1,3,5, 7-tetramethyl-8- (3-pyridinyl) -4,4' -difluoroboradipyrrole
470mg of 3-pyridinecarboxaldehyde and 920mg of 2, 4-dimethylpyrrole are dissolved in 250mL of dry DCM, and a catalytic amount of TFA under argon is added and the mixture is stirred at room temperature for 24 hours. Part of DCM was evaporated under reduced pressure to a solution volume of 70mL, 1.5g of 2, 3-dichloro-5, 6-dicyan p-benzoquinone was added under argon protection, and the mixture was stirred at room temperature for 2 hours. Adding 7mL of triethylamine and 7mL of boron trifluoride diethyl etherate, stirring at room temperature overnight, removing the solvent under reduced pressure, dissolving the residual solid in 150mL of DCM, washing with water for three times, drying with anhydrous sodium sulfate, evaporating the solvent under reduced pressure, and purifying DCM/PE (DCM/PE) by column chromatography to obtain 195mg of an orange solid, wherein the yield is as follows: 13.5%, MS (ESI) M/z ([ M + H)]+):326.2;
2) Synthesis of 2, 6-diiodo-1, 3,5, 7-tetramethyl-8- (3-pyridyl) -4,4' -difluoroboron dipyrrole
Compound 1,3,5, 7-tetramethyl-8- (3-pyridyl) -4,4' -difluoroboradipyrrole (100mg) was placed in a 25mL eggplant-shaped bottle, and HOAc/DCM ═ 1/3(6mL) was added thereto and dissolved. 340mg of N-iodosuccinimide were added, stirred at room temperature for 1h and the reaction was monitored by TLC for completion. 20mL of saturated sodium thiosulfate solution, 20mL of water, 20mL of saturated NaHCO3Washing with an aqueous solution, drying over anhydrous sodium sulfate, evaporating the solvent under reduced pressure, and performing column chromatography on the solvent PE: EA ═ 1:1 to obtain 142mg of a brown solid, yield: 80%, MS (ESI) M/z ([ M + H)]+):578.0。1H NMR(400MHz,CDCl3)δ8.83(d,J=3.3Hz,1H),8.56(s,1H),7.65(d,J=8.0Hz,1H),7.57-7.49(m,1H),2.66(s,6H),1.40(s,6H);
3) Synthesis of Compound 3
The compound 2, 6-diiodo-1, 3,5, 7-tetramethyl-8- (3-pyridinyl) -4,4' -difluoroboradipyrrole (200mg), 9- (2- (2- (2-methoxyethoxy) ethoxy) ethyl) -9H-carbazole-3-carbaldehyde (591mg) was dissolved in toluene (15mL), glacial acetic acid (0.1mL) and piperidine (0.1mL) were added, and the mixture was refluxed in a two-necked flask for 10 hours. After the reaction, the oil bath was removed, dichloromethane and water (50 mL. times.3) were extracted, dried over anhydrous sodium sulfate, filtered and the solvent was evaporated to CH2Cl2Purification by column chromatography with MeOH (30:1, v/v, triethylamine 1%) afforded BODIPY 9200 mg as a green solid. Yield: the content of the active ingredients in the active ingredients is 47%,1H NMR(400MHz,CDCl3)δ8.83(d,J=4.7Hz,1H),8.63(s,1H),8.47(d,J=16.6Hz,2H),8.35-8.34(s,2H),8.15(d,J=7.7Hz,2H),7.87-7.83(m,3H),7.79-7.78(m,1H),7.69(d,J=8.3Hz,1H),7.53-7.47(m,7H),7.25-7.23(m,2H),4.53(t,J=5.2Hz,4H),3.90(t,J=5.4Hz,4H),3.53-3.52(m,8H),3.51-3.50(m,4H),3.41-3.10(m,4H),3.32(s,6H),1.49(s,6H)。
example 4: synthesis of Compound 4
Putting 340mg of the compound in a sealed tube, adding 0.5mL of methyl iodide, reacting for 12 hours at 60 ℃, adding a small amount of DCM to dissolve the methyl iodide completely after the methyl iodide is volatilized completely, adding methyl tert-butyl ether to separate out a purple black solid, filtering, drying to obtain 36mg of a product with the yield of 81 percent,1H NMR(400MHz,CDCl3)δ9.64(s,1H),9.03(s,1H),8.40(d,J=16.3Hz,2H),8.22-8.17(m,4H),8.07(d,J=7.4Hz,2H),7.75-7.68(m,4H),7.41-7.40(m,6H),7.20-7.17(s,2H),4.71(s,3H),4.37-4.36(m,4H),3.79-3.78(m,4H),3.46-3.44(m,8H),3.40-3.39(m,4H),3.36-3.35(m,4H),3.27(s,6H),1.36(s,6H)。
example 5: synthesis of Compound 5
1) Synthesis of 1,3,5, 7-tetramethyl-8- (4-pyridinyl) -4,4' -difluoroboradipyrrole
470mg of 4-pyridinecarboxaldehyde and 920mg of 2, 4-dimethylpyrrole are dissolved in 250mL of dry DCM, and a catalytic amount of TFA under argon is added and the mixture is stirred at room temperature for 24 hours. Part of DCM was evaporated under reduced pressure to a solution volume of 70mL, 1.5g of 2, 3-dichloro-5, 6-dicyan p-benzoquinone was added under argon protection, and the mixture was stirred at room temperature for 2 hours. 7mL of triethylamine and 7mL of boron trifluoride etherate solution were added, under argon protection, and the mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, the residual solid was dissolved in 150mL DCM, washed with water three times, dried over anhydrous sodium sulfate, the solvent was evaporated under reduced pressure and DCM/PE 1/3 was purified by column chromatography to give 130mg of an orange solid, yield: 9 percent.
2) Synthesizing 2, 6-diiodo-1, 3,5, 7-tetramethyl-8- (4-pyridyl) -4,4' -difluoborodipyrrole;
compound 1,3,5, 7-tetramethyl-8- (4-pyridinyl) -4,4' -difluoroboradipyrrole (100mg) was placed in a 25mL eggplant-shaped bottle, and HOAc/DCM ═ 1/3(6mL) was added thereto and dissolved. 340mg of N-iodosuccinimide were added, stirred at room temperature for 1h, monitored by TLCIt should be complete. 20mL of saturated sodium thiosulfate solution, 20mL of water, 20mL of saturated NaHCO3Washing with water solution, drying with anhydrous sodium sulfate, evaporating the solvent under reduced pressure, and performing column chromatography with PE: EA being 1:1 to obtain brown solid 142 mg. Yield: 80 percent. MS (ESI) M/z ([ M + H)]+):578.0。1H NMR(400MHz,CDCl3)δ8.83(d,J=4.1Hz,2H),7.30(d,J=3.7Hz,2H),2.66(s,6H),1.43(s,6H).,
3) Synthesis of Compound 5
The compound 2, 6-diiodo-1, 3,5, 7-tetramethyl-8- (4-pyridinyl) -4,4' -difluoroboradipyrrole (100mg), 9- (2- (2- (2-methoxyethoxy) ethoxy) ethyl) -9H-carbazole-3-carbaldehyde (300mg) was dissolved in toluene (10mL), glacial acetic acid (0.1mL) and piperidine (0.1mL) were added thereto, and the mixture was refluxed in a two-necked flask for 10 hours. After the reaction, the oil bath was removed, dichloromethane and water (25 mL. times.3) were extracted, dried over anhydrous sodium sulfate, filtered and the solvent was evaporated to CH2Cl2Purification by column chromatography with MeOH (30:1, v/v, triethylamine 1%) afforded BODIPY 9120 mg as a green solid. Yield: in the content of 56%,1H NMR(400MHz,CDCl3)δ8.84-8.83(m,2H),8.47(d,J=16.0Hz,2H),8.36-8.35(m,2H),8.25–8.13(m,2H),7.88-7.73(m,4H),7.52-7.48(m,6H),7.39-7.38(m,2H),7.26-7.22(m,2H),4.43-4.41(m,4H),3.91-3.90(m,4H),3.53-3.50(m,8H),3.46-3.45(m,4H),3.41-3.30(m,4H),3.32-3.31(m,6H),1.51(s,6H)。
example 6: synthesis of Compound 6
540 mg of the compound was put in a sealed tube, and 0.5mL of methyl iodide was added thereto to react at 60 ℃ for 12 hours. And (3) adding a small amount of DCM to dissolve the iodomethane when the iodomethane is completely volatilized, adding methyl tert-butyl ether to separate out a purple black solid, performing suction filtration and drying to obtain a product 32mg, wherein the yield is 72%.1H NMR(400MHz,CDCl3)δ9.33-9.32(m,2H),8.39(d,J=16.6Hz,2H),8.24-8.23(m,2H),8.07(d,J=7.0Hz,2H),7.92-7.90(m,2H),7.80(d,J=8.3Hz,2H),7.72(d,J=16.5Hz,2H),7.43-7.42(m,6H),7.15-7.14(m,2H),4.54(s,3H),4.42-4.41(m,4H),3.82-3.81(m,4H),3.48-3.47(m,4H),3.47-3.46(m,4H),3.44-3.43(m,4H),3.40-3.39(m,4H),3.29(s,6H),1.31(s,6H)。
Example 7: singlet oxygen yield test
The compounds BODIPY 1, 2, 3,4, 5, 6, Car-BDP and ZnPc are prepared into 2mL of DMF solution (2 mu M), 2mL of singlet oxygen probe DPBF (100 mu M) is absorbed into six different compound solutions to prepare 4mL of solution, an appropriate cut-off wavelength filter (500nm) is selected according to an ultraviolet visible absorption spectrum, a halogen lamp is 30cm away from the solution, ultraviolet visible scanning is carried out respectively at the irradiation time of 10, 20, 30, 40, 50s and 60s, and the absorbance change at 415nm (the maximum absorption wavelength of the DPBF) is recorded, and the results are shown in Table 1.
TABLE 1 singlet oxygen yield test results for compounds of the invention
Compound (I) | 1 | 3 | 5 | 2 | 4 | 6 | Car-BDP | ZnPc |
ΦΔ | 0.45 | 0.44 | 0.42 | 0.13 | 0.30 | 0.09 | 0.36 | 0.56 |
。
Example 8 was carried out: in vitro anti-tumor cell activity assay
The antitumor activity of the novel photosensitizer in vitro cells is determined by an MTT method, and the Hela, SW-480 and A549 cells are respectively planted in a 96-well plate by 5000 cells per well and are incubated for 24 hours. Discarding culture solution, adding 100 μ L of photosensitizer with a series of different concentrations into each well, setting 5 multiple wells for each concentration, adding DMEM culture solution without sample into positive control group, adding sterilized pure water into blank control group, incubating for 5h, and irradiating with illumination power of 90mW/cm2The cells were irradiated with a light dose of 54J. After 24h incubation, the medium was aspirated, 100. mu.L of 0.5mg/mL MTT in DMEM was added and incubation continued for 4 h. Absorbing MTT culture solution, adding 100 microliter DMSO into each well, shaking a flat table for 10min, and measuring the OD value (570nm) by a microplate reader;
the results are shown in Table 2, and the results show that the compound in the invention shows better antitumor activity, and is obviously improved compared with the compound Car-BDP, wherein the compounds 2,4 and 6 have the inhibitory activity IC on tumor cells under experimental conditions50The value is less than 2 mu M, and the compound can be further used for preparing an anti-tumor cell photosensitizer as a novel anti-tumor medicament.
Table 2 shows the tumor cell inhibitory activity IC of the compounds of the present invention50Value results (unit: μ M).
TABLE 2
Claims (10)
8. use of the pyridine-containing fluoroboron dipyrromethene compound of claim 1 for the preparation of an antitumor photosensitive agent.
9. Use of the pyridine-containing BODIPY compound according to claim 1 for the preparation of a medicament for the treatment of malignant tumors.
10. Use according to claim 9, characterized in that said malignant tumor is a non-specific broad range of tumors selected from the group consisting of gastric, breast, prostate, lung, colon, bladder, ovarian, skin, cervical cancer.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811238213.2A CN111171060B (en) | 2018-10-23 | 2018-10-23 | Pyridine-containing boron dipyrrole and quaternary ammonium salt photosensitizer thereof, and preparation method and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811238213.2A CN111171060B (en) | 2018-10-23 | 2018-10-23 | Pyridine-containing boron dipyrrole and quaternary ammonium salt photosensitizer thereof, and preparation method and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111171060A true CN111171060A (en) | 2020-05-19 |
CN111171060B CN111171060B (en) | 2023-03-17 |
Family
ID=70649762
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811238213.2A Active CN111171060B (en) | 2018-10-23 | 2018-10-23 | Pyridine-containing boron dipyrrole and quaternary ammonium salt photosensitizer thereof, and preparation method and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111171060B (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112194673A (en) * | 2020-10-09 | 2021-01-08 | 安阳工学院 | Combined anti-tumor compound and preparation method and application thereof |
CN114409687A (en) * | 2022-03-02 | 2022-04-29 | 福州大学 | Intelligent photosensitive medicine capable of switching light treatment modes in tumors and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103666458A (en) * | 2013-12-16 | 2014-03-26 | 大连理工大学 | Fluorescent probe for marking and tracking cytoplasmic membranes and preparation method of fluorescent probe |
WO2018071256A1 (en) * | 2016-10-10 | 2018-04-19 | University Of Massachusetts | Ultralow-power near infrared lamp light operable targeted organic nanoparticle photodynamic therapy |
-
2018
- 2018-10-23 CN CN201811238213.2A patent/CN111171060B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103666458A (en) * | 2013-12-16 | 2014-03-26 | 大连理工大学 | Fluorescent probe for marking and tracking cytoplasmic membranes and preparation method of fluorescent probe |
WO2018071256A1 (en) * | 2016-10-10 | 2018-04-19 | University Of Massachusetts | Ultralow-power near infrared lamp light operable targeted organic nanoparticle photodynamic therapy |
Non-Patent Citations (1)
Title |
---|
JUERGEN BARTELMESS ET AL.: "Preparation and characterization of multi-cationic BODIPYs and their synthetically versatile precursors", 《DYES AND PIGMENTS》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112194673A (en) * | 2020-10-09 | 2021-01-08 | 安阳工学院 | Combined anti-tumor compound and preparation method and application thereof |
CN114409687A (en) * | 2022-03-02 | 2022-04-29 | 福州大学 | Intelligent photosensitive medicine capable of switching light treatment modes in tumors and preparation method and application thereof |
CN114409687B (en) * | 2022-03-02 | 2024-01-30 | 福州大学 | Photosensitive medicine capable of switching light treatment modes in tumor and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN111171060B (en) | 2023-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105175410B (en) | Compound in triazine class and preparation method thereof and antitumor application thereof | |
CN108727256B (en) | Photosensitizer based on triphenylamine polypyridine salt and preparation method and application thereof | |
CN108440586B (en) | Two azole derivatives of fluorine boron of cumarin modification and its preparation and application | |
CN109796483B (en) | Water-soluble cationic photosensitizer and preparation and application thereof | |
CN102675323B (en) | Pyrrole-[2, 1-f] [1, 2 and 4] triazine derivative and antitumor effect thereof | |
CN102584780B (en) | Glaucocalyxin derivative as well as preparing method and application thereof | |
CN109575061B (en) | Water-soluble anticancer photosensitizer and preparation and application thereof | |
CN111171060B (en) | Pyridine-containing boron dipyrrole and quaternary ammonium salt photosensitizer thereof, and preparation method and application thereof | |
WO2022199547A1 (en) | 7,9-dihydropurine derivative and pharmaceutical purpose thereof | |
CN111592482B (en) | PH reversible activation type photo-thermal/photodynamic/fluorescent integrated probe molecule | |
CN109081852B (en) | Dual-targeting phthalocyanine anticancer photosensitizer and preparation method thereof | |
CN105949222B (en) | A kind of water-soluble acylhydrazone class Schiff porphyrin metal Cu (II) complexs and its synthesis and application | |
CN110857310B (en) | Polyamphidine ruthenium complex with photoactivity and application thereof | |
CN111303026A (en) | Propenone derivative of enrofloxacin and preparation method and application thereof | |
CN112500293B (en) | 1,1' -biphenyl-2, 6-diphenol compound and application thereof | |
CN106279189B (en) | A kind of quinoline derivatives and preparation method thereof and application in preparation of anti-tumor drugs | |
CN110092789B (en) | Indolo [2,3-b ] carbazole derivative and application thereof | |
CN101475574B (en) | Camptothecin derivative, and preparation and use thereof | |
CN104098457B (en) | Tetrahydrocurcumin analogue, preparation and application thereof | |
CN102134244A (en) | Medical photosensitizer and preparation method thereof | |
CN115368347A (en) | Near-infrared molecules with PTT and PDT effects and application thereof | |
CN102068428B (en) | Dihydroporphin photosensitizer and preparation and application thereof | |
CN109020904B (en) | 2-aryl-4-aroyl-5-alicyclic amino-2H-triazole compound and application thereof | |
CN108484623B (en) | Camptothecin derivative and preparation method and application thereof | |
CN112824408A (en) | Propenone derivative of moxifloxacin and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |